FINWIRES · TerminalLIVE
FINWIRES

Solid Biosciences Says SGT-003 Gets EU Orphan Drug Designation for Duchenne Muscular Dystrophy

By

-- Solid Biosciences (SLDB) said Tuesday the European Commission has granted orphan drug designation to its investigational therapy SGT-003 for Duchenne muscular dystrophy.

This decision followed a positive recommendation from the European Medicines Agency's Committee for Orphan Medicinal Products, the company said.

SGT-003 already has been granted fast track, orphan drug, and rare pediatric disease designations by the US Food and Drug Administration, the company said, adding that the therapy is currently being tested in two clinical trials aimed at supporting regulatory approval in different countries.

Price: $7.54, Change: $+0.04, Percent Change: +0.47%

Related Articles

Australia

Velo3D Closes $50 Million Registered Direct Offering

Velo3D (VELO) said Tuesday it closed an underwritten registered direct offering of nearly 3.6 million common shares for gross proceeds of about $50 million.Net proceeds will be used for working capital and general corporate purposes, the company added.Price: $13.76, Change: $-0.57, Percent Change: -3.98%

$VELO
Australia

First Financial Bankshares Ups Quarterly Dividend 15.8% to $0.22 a Share, Payable July 1 to Holders of Record June 12

Price: $32.61, Change: $+0.18, Percent Change: +0.56%

$FFIN
Mining & Metals

First Atlas Resources Sells MacKenzie East Claims in Quebec to LaFleur Minerals

First Atlas Resources (HHE.CN) on Tuesday said it agreed to sell a 100% interest in its MacKenzie East Claims located in the Val-d'Or gold camp, Quebec, to LaFleur Minerals (LFLR.CN) in a cash and stock deal.LaFleur will buy the property in exchange for $30,000 in cash, and 175,000 shares of LaFleur Minerals. The cash portion is payable within 48 hours of execution of the agreement, the company said.The share consideration will be issued upon receipt of exchange acceptance or, if not required, within five business days following closing of the deal. The property consists of 46 mineral claims covering about 1,781 hectares.The deal allows First Atlas to monetize a non-core asset while retaining exposure to the upside of the Val-d'Or region through its equity interest in LaFleur, it added.Shares of First Atlas were last seen down $0.005 to $0.10 on the Canadian Securities Exchange.

$HHE.CN$LFLR.CN